New combo therapy aims to tackle tough prostate cancer
Disease control
Recruiting now
This phase II trial is testing whether adding two hormone-blocking drugs, relugolix and enzalutamide, to standard radiation therapy can better control very-high-risk prostate cancer. About 50 men will receive the combination for 18 months. The main goal is to see if it lowers the…
Phase: PHASE2 • Sponsor: Sean Sachdev • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC